Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Cabazitaxel—the taxane of choice in the new mCRPC landscape?

Nature Reviews Urology volume 11, pages 370–372 (2014)Cite this article

Subjects

Cabazitaxel, a next-generation taxane, retains its efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress on new androgen receptor (AR)-targeted agents such as abiraterone acetate or enzalutamide. These findings are reinforced by in vitro preclinical data confirming cross-resistance between abiraterone and enzalutamide, but not between cabazitaxel and AR-targeted agents.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Fitzpatrick, J. M. et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European expert consensus panel. Eur. J. Cancer 50, 1617–1627 (2014).

    Article  Google Scholar 

  2. Al Nakouzi, N. et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.04.015.

  3. Zong, Y. & Goldstein, A. S. Adaptation or selection—mechanisms of castration-resistant prostate cancer. Nat. Rev. Urol. 10, 90–98 (2013).

    Article  CAS  Google Scholar 

  4. Pezaro, C. J. et al. Visceral disease in castration-resistant prostate cancer. Eur. Urol. 65, 270–273 (2014).

    Article  CAS  Google Scholar 

  5. Arora, V. K. et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155, 1309–1322 (2013).

    Article  CAS  Google Scholar 

  6. Thadani-Mulero, M. et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Clin. Cancer Res. 74, 2270–2282 (2014).

    CAS  Google Scholar 

  7. Fitzpatrick, J. M. & De Wit, R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur. Urol. 65, 1198–1204 (2014).

    Article  CAS  Google Scholar 

  8. Pezaro, C. J. et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2013.11.044.

  9. Angelergues, A. et al. Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter. J. Clin. Oncol. 31, 5095 (2013).

    Article  Google Scholar 

  10. Van Soest, R. J. et al. In vivo efficacy docetaxel and cabazitaxel in a cell-line based xenograft of castration-resistant prostate cancer previously treated with enzalutamide. J. Clin. Oncol. 32, 5046 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. European Georges Pompidou Hospital, 20 rue Leblanc, Paris, 75015, France

    Stéphane Oudard & Antoine Angelergues

Authors
  1. Stéphane Oudard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antoine Angelergues
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stéphane Oudard.

Ethics declarations

Competing interests

The authors declare competing interests with the following companies: Bayer, Sanofi, Astellas, Janssen, Ferring, and Ipsen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oudard, S., Angelergues, A. Cabazitaxel—the taxane of choice in the new mCRPC landscape?. Nat Rev Urol 11, 370–372 (2014). https://doi.org/10.1038/nrurol.2014.144

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2014.144

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing